Hostname: page-component-7479d7b7d-qlrfm Total loading time: 0 Render date: 2024-07-12T01:10:49.357Z Has data issue: false hasContentIssue false

Vesicular Lipid Nanoparticles (Liposomes) for the Treatment of Medical Device Infections

Published online by Cambridge University Press:  25 March 2011

Erik Taylor
Affiliation:
School of Engineering and Department of Orthopaedics, Brown University Providence, RI 02917, USA
Anubhav Kaviratna
Affiliation:
Department of Biosciences and Bioengineering, Indian Institute of Technology Mumbai, 400076, India
Rinti Banerjee
Affiliation:
Department of Biosciences and Bioengineering, Indian Institute of Technology Mumbai, 400076, India
Thomas J. Webster
Affiliation:
School of Engineering and Department of Orthopaedics, Brown University Providence, RI 02917, USA
Get access

Abstract

Liposomes (a phospholipid bi-layer which can be formulated to contain drugs or other reagents) composed of endogenous phospholipid dipalmitoylphosphatidylcholine (DPPC) in combination with dioleoylphosphatidylethanolamine (DOPE), lauric acid, and silver sulfadiazine were made into vesicular nanoparticles in this study using an optimized extrusion technique. Liposomes were then tested for antibacterial activity against a range of bacteria species including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Bacillus subtilis (all are relevant human pathogens known to infect implants) and were also challenged to prevent the growth of adherent biofilms (a robust slimy extracellular matrix) through an in vitro assay relevant to device related infections. It was found that all liposomes reduced bacterial growth, and, most importantly, liposomes containing DPPC and DOPE reduced biofilm formation better than the commercially available antibiotic silver sulfadiazine. These results indicated for the first time that such liposomes might be a better approach to prevent device related infections.

Type
Research Article
Copyright
Copyright © Materials Research Society 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literature Cited

[1] Hall-Stoodley, L., Costerton, J.W., Stoodley, P., Nat Rev Micro 2 (2004) 95108.Google Scholar
[2] Betsch, B.Y., Eggli, S., Siebenrock, K.A., Tauber, M.G., Muhlemann, K., Clinical Infectious Diseases 46 (2008) 12211226.Google Scholar
[3] Kenny, J.G., Ward, D., Josefsson, E., Jonsson, I.-M., Hinds, J., Rees, H.H., Lindsay, J.A., Tarkowski, A., Horsburgh, M.J., PLoS ONE 4 (2009) e4344.Google Scholar
[4] Drulis-Kawa, Z., Dorotkiewicz-Jach, A., International Journal of Pharmaceutics 387 (2010) 187198.Google Scholar
[5] Silver, S., Phung, L.T., Silver, G., Journal of Industrial Microbiology & Biotechnology 33 (2006) 627634.Google Scholar
[6] Boles, B.R., Singh, P.K., Proceedings of the National Academy of Sciences of the United States of America 105 (2008) 1250312508.Google Scholar
[7] Singh, R., Ray, P., Das, A., Sharma, M., Journal of Medical Microbiology 58 (2009) 10671073.Google Scholar